concentr
ratio
purin
nucleotid
deoxynucleotid
nucleotid
pool
highli
regul
order
maintain
proper
function
genet
stabil
mammalian
imbal
deoxi
nucleotid
pool
may
mutagen
may
lead
variou
diseas
combin
immunodefici
loss
purin
nucleosid
phosphorylas
pnp
function
hyperuricemia
loss
hypoxanthineguanin
phosphoribosyltransferas
hgprt
function
cancer
uncontrol
activ
dehydrogenas
impdh
xanthosin
monophosph
xmp
figur
import
intermedi
de
novo
synthesi
guanin
nucleotid
concentr
essenti
mainten
guanin
nucleotid
xmp
serv
substrat
guanosin
monophosph
produc
guanosin
monophosph
gmp
xmp
form
either
inosin
monophosph
imp
impdh
via
salvag
pathway
use
hypoxanthin
xanthin
phosphoribosyltransferas
xmp
level
regul
hydrolyz
xmp
xanthosin
contrast
correspond
deoxyribonucleotid
analogu
dxmp
figur
dxtp
catabol
product
dgmp
dgtp
enzymat
hydrolysi
form
defect
purin
nucleotid
metabol
involv
deaminas
enzym
chemic
dgmpdgtp
via
noxmedi
nitros
process
lead
substanti
incorpor
xanthin
nucleotid
dna
andor
subsequ
rna
miscod
moreov
deamin
nucleotid
interfer
rna
function
noncod
cell
physiolog
homeostasi
concentr
ratio
potenti
mutagen
nucleotid
intermedi
idp
itp
xtp
maintain
housekeep
especi
nudix
famili
hydrolyz
correspond
nucleosid
di
triphosph
main
function
housekeep
enzym
prevent
minim
incorpor
noncanon
nucleotid
dnarna
unfortun
literatur
housekeep
enzym
hydrolyz
dxdpdxtp
quit
rare
date
dnacontain
envelop
virus
larg
herpesvirida
famili
includ
herp
simplex
viru
hsv
varicellazost
viru
vzv
cytomegaloviru
cmv
epsteinbarr
viru
ebv
although
current
antiherpet
therapi
use
power
antivirot
nucleosid
analogu
acyclovir
acv
penciclovir
vidarabin
ganciclovir
gcv
acycl
nucleosid
phosphon
anp
cidofovir
cdv
figur
diphosph
mimic
mani
drug
insensit
virus
identifi
clinic
origin
viru
resist
hsv
vzv
cmv
come
mostli
treatment
use
dna
polymeras
inhibitor
acv
gcv
variou
alter
viral
thymidin
kinas
gene
hsv
vzv
protein
kinas
cmv
andor
viral
dna
polymeras
gene
hsv
vzv
cmv
may
recent
literatur
presenc
resist
herpesvirus
consid
serious
case
immunocompromis
individu
evid
urgent
need
novel
potent
antiherpet
agent
high
barrier
resist
develop
mimic
natur
nucleotid
avoid
first
phosphoryl
step
repres
potent
group
antivir
agent
anp
convert
insid
cell
diphosph
anppp
target
dna
polymeras
viral
andor
nucleosid
triphosph
analogu
act
competit
inhibitor
andor
altern
substrat
respect
enzym
later
case
lead
termin
dna
chain
although
anp
deriv
xanthin
studi
potenti
antivir
agent
name
phosphonomethoxi
propyl
deriv
fpmpx
gener
lack
interest
compound
probabl
caus
rel
complic
synthesi
sinc
simpl
alkyl
xanthin
base
expect
give
mixtur
sever
regioisom
well
polyalkyl
product
recent
simpl
highyield
synthesi
xanthin
anp
exploit
mwassist
hydrolysi
correspond
deriv
report
synthesi
antivir
evalu
seri
xanthinebas
anp
compound
figur
design
nonhydrolyz
analogu
dxmpxmp
synthesi
phosphonomethoxi
ethyl
xanthin
pmex
scheme
xanthin
analogu
wellknown
antivir
agent
adefovir
pmea
report
group
microwaveassist
hydrolysi
deriv
aqueou
hcl
afford
desir
xanthin
compound
yield
synthesi
target
anp
compound
scheme
previous
guanin
contain
anp
exploit
start
materi
standard
diazot
compound
follow
afford
desir
xanthinebas
anp
moder
good
yield
sinc
pmex
exhibit
promis
antivir
properti
decid
prepar
sever
pmex
prodrug
order
improv
compound
permeabl
might
limit
neg
charg
compound
first
deriv
scheme
prepar
yield
correspond
deriv
use
mention
procedur
compound
expect
enzymat
convert
deamin
pmex
analog
compound
acycl
nucleotid
analogu
potent
antineoplast
activ
abacavir
carbocycl
nucleosid
use
treatment
hiv
infect
next
pmex
hexadecyloxypropyl
hdp
monoest
scheme
prodrug
approach
develop
hostetl
et
al
mimic
natur
prepar
pmex
hexadecyloxypropyl
alcohol
via
dccmediat
coupl
yield
similarli
phosphon
ester
scheme
bear
chain
prepar
procedur
yield
final
bisamid
prodrug
scheme
obtain
yield
start
pmex
isopropyl
ester
lphenylalanin
use
previous
describ
procedur
develop
order
confirm
expect
mode
action
pmex
ie
viral
dna
polymeras
inhibit
correspond
phosphonodiphosph
scheme
analogu
natur
nucleosid
triphosph
also
prepar
twostep
synthesi
via
morpholid
afford
hplc
purif
desir
triphosph
mimic
low
yield
synthes
xanthinebas
anp
compound
evalu
inhibitori
activ
wide
rang
dna
rna
virus
human
embryon
lung
hel
cell
herp
simplex
ko
strain
herp
simplex
g
strain
thymidin
kinas
defici
acv
resist
herp
simplex
ko
acvr
vaccinia
viru
vesicular
stomat
viru
human
cytomegaloviru
hcmv
strain
davi
strain
vzv
tk
vzv
strain
vzv
strain
hela
cell
cultur
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
rsv
vero
cell
cultur
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
yellow
fever
viru
crfk
cell
cultur
felin
corona
viru
fipv
mdck
cell
cultur
influenza
viru
subtyp
influenza
b
viru
gcv
cdv
acv
brivudin
bvdu
zalcitabin
zanamivir
alovudin
amantadin
rimantadin
ribavirin
dextran
sulfat
molecular
weight
mycophenol
acid
hippeastrum
hybrid
agglutinin
hha
urtica
dioica
agglutinin
uda
use
refer
compound
antivir
activ
express
ie
compound
concentr
requir
decreas
viru
plaqu
format
vzv
virusinduc
cytopathogen
virus
none
compound
show
activ
rna
virus
compound
abl
inhibit
replic
herpesvirus
tabl
pmex
emerg
activ
compound
vzv
hcmv
activ
refer
drug
acv
tk
oka
strain
pmex
versu
acv
contrast
acv
compound
remain
activ
vzv
strain
pmex
also
inhibit
replic
hcmv
valu
order
magnitud
refer
antihcmv
drug
gcv
pmex
cytostat
concentr
hel
cell
thu
compound
potent
also
select
calcul
select
indic
ratio
vzv
oka
strain
respect
hcmv
davi
strain
respect
compound
respect
fold
fold
less
activ
pmex
vzv
hcmv
howev
compound
inhibit
replic
equival
valu
rang
pmex
lack
activ
vaccinia
viru
hpmpx
compound
sisom
racem
mixtur
weak
inhibitor
poxviru
tabl
anp
includ
pmex
polar
compound
show
sever
limit
bioavail
increas
likelihood
good
cell
wall
permeabl
sever
differ
prodrug
approach
test
pmex
tabl
compound
complet
inact
assay
phosphon
ester
biamid
prodrug
display
potent
antiherpesviru
activ
might
explain
insuffici
prodrug
activ
cell
hdppmex
prodrug
prove
fold
vzv
fold
hcmv
fold
hsv
activ
compound
parent
compound
although
concomit
increas
cytostat
activ
also
observ
indic
success
increas
cell
uptak
order
determin
whether
dna
polymeras
actual
target
action
pmex
compound
evalu
wellcharacter
mutant
virus
alik
anp
pmex
remain
activ
virus
bear
mutat
viral
tk
figur
importantli
increas
pmex
magnitud
measur
anp
found
dna
polymeras
mutant
virus
indic
target
action
activ
form
compound
ie
pmexpp
herpesviru
dna
polymeras
inhibitori
activ
diphosph
form
pmex
pmexpp
evalu
enzymat
assay
herp
vzv
hcmv
dna
polymeras
compar
cellular
dna
polymeras
tabl
inhibit
acv
triphosph
pyrophosph
analogu
foscarnet
pfa
determin
studi
comparison
compound
inhibitori
toward
cellular
dna
polymeras
inhibit
vzv
dna
polymeras
dgtp
use
competit
radiolabel
substrat
howev
activ
highest
concentr
could
detect
hcmv
dna
polymeras
either
dgtp
dttp
use
competit
radiolabel
substrat
data
suggest
compound
poor
inhibitor
hcmv
dna
polymeras
compound
may
requir
hcmv
dna
polymeras
interact
protein
replic
complex
activ
also
possibl
pmex
metabolit
target
anoth
viral
enzym
confirm
compound
target
viral
dna
polymeras
pmexresist
herpesvirus
select
pressur
pmex
character
genotyp
phenotyp
start
compound
chemic
purchas
commerci
supplier
prepar
accord
publish
procedur
solvent
dri
standard
procedur
solvent
evapor
kpa
analyt
tlc
perform
plate
kieselgel
f
merck
column
chromatographi
perform
silica
gel
mesh
merck
revers
phase
hplc
separ
perform
water
delta
instrument
water
tunabl
absorb
detector
use
column
phenomenex
gemini
mm
flow
mlmin
prepar
column
nmr
spectra
record
bruker
avanc
mhz
mhz
mhz
spectromet
tm
ppm
ppm
nmr
intern
standard
referenc
residu
solvent
signal
hr
ms
spectra
taken
ltq
orbitrap
xl
spectromet
puriti
test
compound
determin
hplc
linear
gradient
higher
synthesi
compound
perform
compound
g
mmol
use
previous
describ
microwaveassist
heat
min
compound
aqueou
hcl
follow
solvent
remov
precipit
form
watermethanol
mixtur
gave
g
white
solid
analyt
data
agreement
publish
treatment
mg
mmol
method
afford
mg
white
solid
nmr
naod
dd
jgem
hz
hz
dd
jgem
hz
hz
dd
jgem
hz
hz
dd
jgem
hz
hz
dd
jgem
hz
hz
dd
jgem
hz
hz
nmr
naod
jcocp
hz
jcp
hz
mz
mh
hrm
mz
mh
calcd
found
treatment
mg
mmol
method
gave
mg
white
solid
nmr
nmr
spectra
ident
compound
mz
mh
hrm
mz
mh
calcd
found
c
ml
treatment
mg
mmol
method
gave
mg
white
solid
nmr
bs
ddd
hz
jgem
hz
hz
ddd
hz
jgem
hz
hz
dd
jgem
hz
hz
dd
jgem
hz
hz
bddtd
hz
hz
hz
hz
dd
jgem
hz
hz
dd
jgem
hz
hz
nmr
hz
dd
hz
hz
hz
hz
hrm
mz
mh
calcd
found
c
ml
treatment
mg
mmol
method
gave
mg
white
solid
analyt
data
ident
compound
c
ml
treatment
mg
mmol
method
gave
mg
white
solid
nmr
bs
dd
jgem
hz
hz
dd
jgem
hz
hz
dd
jgem
hz
hz
dd
jgem
hz
hz
hz
nmr
hz
observ
hrm
mz
mh
calcd
found
c
ml
treatment
mg
mmol
method
gave
mg
white
solid
nmr
bs
nhch
hz
hz
hz
bs
nhch
nmr
hz
hz
chnh
hrm
mz
mh
calcd
found
suspens
mg
mmol
hexadecyloxi
mg
mmol
anhydr
pyridin
ml
preheat
dicyclohexylcarbodiimid
mg
mmol
anhydr
pyridin
ml
ad
reaction
mixtur
stir
h
solvent
evapor
crude
product
purifi
use
silica
gel
chromatographi
give
mg
white
amorph
solid
nmr
q
hz
hz
hz
hz
p
hz
hz
nmr
hz
hz
hz
hz
hrm
esi
mz
mna
calcd
found
suspens
mg
mmol
mg
mmol
anhydr
pyridin
ml
preheat
dicyclohexylcarbodiimid
mg
mmol
anhydr
pyridin
ml
ad
reaction
mixtur
stir
h
solvent
evapor
crude
product
purifi
use
silica
gel
chromatographi
give
mg
white
amorph
solid
nmr
q
hz
hz
nmr
hz
hz
hz
hz
nmr
ref
ppm
hrm
esi
mz
mna
calcd
found
tmsbr
ad
mixtur
mg
mmol
dri
pyridin
ml
dmf
ml
reaction
mixtur
stir
h
volatil
remov
moisturesensit
product
perman
kept
argon
solid
isopropyl
ester
lphenylalanin
hydrochlorid
mg
mmol
ad
silyl
intermedi
argon
follow
dri
pyridin
ml
dri
mmol
mixtur
preheat
freshli
prepar
solut
g
mmol
triphenylphosphin
g
mmol
pyridin
ml
ad
result
mixtur
stir
h
reaction
mixtur
evapor
vacuo
residu
purifi
column
chromatographi
meoh
mixtur
hexan
etoac
follow
revers
phase
column
chromatographi
meoh
water
give
mg
amorph
white
solid
nmr
bs
nh
chipr
chnh
chnh
chnh
chnh
ch
hz
nmr
coo
hz
chipr
jcp
hz
nhch
hrm
esi
mz
h
calcd
found
pmex
morpholid
morpholin
ml
mmol
ad
mixtur
mg
mmol
ml
vv
preheat
solut
dicyclohexylcarbodiimid
mg
mmol
ml
vv
ad
dropwis
boil
reaction
mixtur
period
h
mixtur
heat
overnight
cool
solid
filter
mixtur
concentr
half
volum
dilut
water
ml
aqueou
solut
extract
diethyl
ether
ml
organ
layer
dri
evapor
dryness
crude
morpholid
use
directli
pyrophosph
coupl
pyrophosph
coupl
prepar
morpholid
mmol
care
dri
treat
solut
dmf
ml
room
temperatur
h
product
precipit
diethyl
ether
ml
solid
wash
diethyl
ether
ml
precipit
product
dissolv
teab
ml
purifi
column
pack
hq
ml
use
gradient
teab
water
product
coevapor
sever
time
water
convert
sodium
salt
form
dowex
na
cycl
lyophylis
afford
mg
white
amorph
solid
nmr
hz
hz
hz
q
j
hz
j
hz
nmr
j
hz
dm
j
hz
dd
j
hz
j
hz
hrm
mz
mh
calcd
found
compound
evalu
differ
herpesvirus
includ
herp
simplex
viru
type
strain
ko
thymidin
kinasedefici
ko
strain
resist
acv
acvr
herp
simplex
viru
type
strain
g
vzv
strain
oka
vzv
strain
human
cytomegaloviru
hcmv
strain
davi
well
vaccinia
viru
adeno
vesicular
stomat
viru
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
rsv
fipv
influenza
viru
subtyp
influenza
b
viru
antivir
assay
base
inhibit
virusinduc
cytopath
plaqu
format
human
embryon
lung
hel
fibroblast
african
green
monkey
kidney
cell
vero
human
epitheli
cervix
carcinoma
cell
hela
crandellre
felin
kidney
cell
crfk
madin
darbi
canin
kidney
cell
mdck
confluent
cell
cultur
microtit
plate
inocul
viru
viru
dose
infect
cell
cultur
pfu
cell
cultur
incub
presenc
vari
concentr
test
compound
viral
cytopath
plaqu
format
vzv
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
compound
concentr
requir
reduc
virusinduc
cytopath
viral
plaqu
format
compound
evalu
sever
tk
dna
polymeras
mutant
deriv
refer
ko
strain
cpe
reduct
assay
use
refer
drug
acv
gcv
bvdu
foscavir
cdv
adefovir
adv
cytotox
test
compound
express
minimum
cytotox
concentr
compound
concentr
caus
microscop
detect
alter
cell
morpholog
altern
cytostat
activ
test
compound
measur
base
inhibit
cell
growth
hel
cell
seed
rate
cellswel
microtit
plate
allow
prolifer
h
medium
contain
differ
concentr
test
compound
ad
three
day
incub
cell
number
determin
coulter
counter
cytostat
concentr
calcul
compound
concentr
requir
reduc
cell
prolifer
rel
number
cell
untreat
control
inhibitori
effect
pmexpp
human
viral
vzv
hcmv
dna
polymeras
determin
previous
describ
use
activ
calf
thymu
dna
three
unlabel
dntp
rate
limit
tritiumlabel
dntp
serial
dilut
pmexpp
foscarnet
pyrophosph
acyclovir
triphosph
includ
refer
compound
inhibitori
concentr
compound
concentr
requir
inhibit
polymerasecatalyz
dna
synthesi
determin
seri
novel
anp
bear
xanthin
nucleobas
prepar
evalu
potenti
antivir
properti
two
synthet
approach
exploit
synthesi
target
compound
recent
develop
mwassist
hydrolysi
deriv
b
wellestablish
correspond
guanin
analogu
prepar
anp
test
wide
rang
dna
rna
virus
two
compound
exhibit
antivir
activ
pmex
activ
vzv
hcmv
valu
hpmpx
sisom
racem
mixtur
exhibit
moder
weak
activ
rang
vzv
hcmv
vaccinia
viru
pmex
activ
compound
vzv
seri
tk
oka
strain
equipot
refer
drug
acv
contrast
acv
pmex
anp
activ
independ
first
phosphoryl
step
remain
activ
vzv
strain
hexadecyloxypropyl
monoest
deriv
pmex
compound
slightli
improv
antihsv
potenc
parent
compound
valu
studi
pmex
diphosph
analogu
pmexpp
suggest
compound
act
inhibitor
herpesviru
dna
polymeras
vzv
studi
repres
first
report
xanthin
contain
anp
potent
antivir
properti
urg
studi
variou
xanthin
nucleotid
analogu
potenti
antivir
agent
